<p> [ad_1]<br />
</p>
<div>
<div class="entry-content column content primary is-two-thirds">
<div class="" style="padding-bottom: 10px;">
<div class="">
<p>
						<span class="tag is-dark is-uppercase">Investing</span>
				</p>
<div class="byline-container">
<div class="post-date is-italic has-text-grey is-size-7 has-text-weight-medium ">
<p>November 16, 2022 9:21 pm</p>
</p></div>
</p></div>
</p></div>
</p></div>
</p></div>
<p>The IPO market has been slow this year as investors’ risk appetite for new issues hit a record low. As of last month, there were just 161 initial public offerings in 2022, the fewest since 2016. In 2021, there were 1,035 IPOs.</p>
<p>Poor performance of recent IPOs is another reason investors and companies are particularly cautious this year. Amid such a backdrop, let’s take a look at the 10 best-performing IPOs in 2022, as of the end of October.</p>
<h2>The 10 Best-Performing IPOs In 2022 So Far</h2>
<p>We used the year-to-date return of companies that went public this year through October to determine the 10 best-performing IPOs in 2022 so far.</p>
<ol start="10">
<li>
<h3>TPG (32%)</h3>
</li>
</ol>
<p>Founded in 1992 and headquartered in Fort Worth, Texas, TPG Inc (NASDAQ:TPG) is a diversified alternative asset management firm. TPG shares are up by over 20% in the last three months, including a gain of almost 38% in the last month.</p>
<p>As of the time of this writing, TPG shares are trading at around $38 with a 52-week range of $23.09 to $44.43, giving the company a market capitalization of more than $11 billion. The company went public in January.</p>
<ol start="9">
<li>
<h3>Nuvectis Pharma (36%)</h3>
</li>
</ol>
<p>Founded in 2020 and headquartered in Fort Lee, New Jersey, this company develops novel targeted small-molecule therapeutics to treat cancer. Nuvectis Pharma Inc (NASDAQ:NVCT) shares are down by more than 24% in the last three months, including a decline of more than 4% in the last month.</p>
<p>As of the time of this writing, Nuvectis Pharma shares are trading at around $6.80 with a 52-week range of $3.08 to $20.92, giving the company a market capitalization of more than $101 million. The company went public in February.</p>
<ol start="8">
<li>
<h3>Golden Sun Education Group (42%)</h3>
</li>
</ol>
<p>Founded in 1997 and headquartered in Shanghai, China, this company offers private education services. Golden Sun Education Group Ltd (NASDAQ:GSUN) shares are down by over 89% in the last three months, including a decline of more than 74% in the last month.</p>
<p>As of the time of this writing, Golden Sun Education shares are trading at around $5.70 with a 52-week range of $4.94 to $95, giving the company a market capitalization of more than $111 million. The company went public in February.</p>
<ol start="7">
<li>
<h3>Mobileye Global (42%)</h3>
</li>
</ol>
<p>Founded in 1999 and headquartered in Jerusalem, Israel, this company develops advanced driver assistance systems and autonomous driving technologies and solutions.</p>
<p>As of the time of this writing, Mobileye Global Inc (NASDAQ:MBLY) shares are trading at around $31 with a 52-week range of $24.85 to $31.88, giving the company a market capitalization of more than $23 billion. The company went public in October.</p>
<ol start="6">
<li>
<h3>Arcellx (45%)</h3>
</li>
</ol>
<p>Founded in 2014 and headquartered in Gaithersburg, Maryland, this company develops innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx Inc (NASDAQ:ACLX) shares are up by over 11% in the last three months, including a gain of almost 15% in the last month.</p>
<p>As of the time of this writing, Arcellx shares are trading at around $21 with a 52-week range of $6.04 to $26.91, giving the company a market capitalization of more than $945 million. The company went public in February.</p>
<ol start="5">
<li>
<h3>Credo Technology Group Holding (54%)</h3>
</li>
</ol>
<p>Founded in 2014 and headquartered in San Jose, California, this company develops connectivity solutions and products for the data infrastructure market. Credo Technology Group Holding Ltd (NASDAQ:CRDO) shares are up by almost 1% in the last three months after a gain of more than 39% in the last month.</p>
<p>As of the time of this writing, Credo Technology shares are trading at around $15 with a 52-week range of $8.61 to $18, giving the company a market capitalization of more than $2.1 billion. The company went public in January.</p>
<ol start="4">
<li>
<h3>CinCor Pharma (69%)</h3>
</li>
</ol>
<p>Founded in 2018 and headquartered in Waltham, Massachusetts, this company is developing treatments for hypertension and other cardio-renal diseases. CinCor Pharma Inc (NASDAQ:CINC) shares are down by almost 23% in the last three months, including a decline of more than 18% in the last month.</p>
<p>As of the time of this writing, CinCor Pharma shares are trading at around $27 with a 52-week range of $13 to $43.15, giving the company a market capitalization of more than $1.2 billion. The company went public in January.</p>
<ol start="3">
<li>
<h3>Amylyx Pharmaceuticals (87%)</h3>
</li>
</ol>
<p>Founded in 2013 and headquartered in Cambridge, Massachusetts, this company offers disease-modifying solutions for neurodegenerative diseases. Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares are up by almost 44% in the last three months after a decline of almost 1% in the last month.</p>
<p>As of the time of this writing, Amylyx Pharmaceuticals shares are trading at around $34 with a 52-week range of $6.51 to $38.77, giving the company a market capitalization of more than $2.3 billion. The company went public in January.</p>
<ol start="2">
<li>
<h3>AMTD Digital (131%)</h3>
</li>
</ol>
<p>Founded in 2019 and headquartered in Hong Kong, this company develops digital solutions applications on the AMTD SpiderNet platform. AMTD Digital Inc (NYSE:HKD) shares are down by over 90% in the last three months, including a decline of more than 33% in the last month.</p>
<p>As of the time of this writing, AMTD Digital shares are trading at around $18 with a 52-week range of $12.05 to $2,555.30, giving the company a market capitalization of more than $3.1 billion. The company went public in July.</p>
<ol>
<li>
<h3>Belite Bio (318%)</h3>
</li>
</ol>
<p>Founded in 2018 and headquartered in San Diego, California, this company develops drugs to treat eye diseases. Belite Bio Inc (NASDAQ:BLTE) shares are down by almost 8% in the last three months after a decline of more than 17% in the last month.</p>
<p>As of the time of this writing, Belite Bio shares are trading at around $25 with a 52-week range of $8.80 to $44.70, giving the company a market capitalization of more than $622 million. The company went public in April.</p>
<p><i>This article originally appeared on ValueWalk</i></p>
<p>				<!-- #post-footer--></p></div>

These Are the 10 Best-Performing IPOs in 2022 Through October – Darlinez News.
